{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-139288","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.877574+00:00","generated_at":"2026-05-28T23:46:46.350952+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics receives Nasdaq delisting notice for failure to meet MVLS minimum of $50M","bullets":["Nasdaq notified HCW Biologics on Dec 17, 2024 that its securities are subject to delisting due to MVLS below $50M threshold for 30 consecutive business days.","Company failed to regain compliance by the Dec 16, 2024 deadline after a 180-day compliance period that began June 20, 2024.","HCW Biologics plans to timely request a hearing before Nasdaq Hearing Panel, which will stay delisting pending hearing and possible extension.","Panel may grant up to 180-day extension; no assurance of continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-139288","json":"https://secwatch.observer/filing/0000950170-24-139288.json","markdown":"https://secwatch.observer/filing/0000950170-24-139288.md","text":"https://secwatch.observer/filing/0000950170-24-139288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024139288/0000950170-24-139288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024139288/hcwb-20241217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:46:46.350952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d137fda004b3d84b671ae5c65235dec321bdca0","claim":"HCW Biologics Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(3)(A)).","evidence_excerpt":"December 17, 2024, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the hearing and the expiration of any extension that may be granted to the Company following the hearing. At the hearing, the Company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, and request an extension of time","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017024139288/0000950170-24-139288-index.htm","confidence":0.99,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5450(b)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}